Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Barbara A. Konkle, Christopher E. Walsh, Miguel A. Escobar, Neil C. Josephson, Guy Young, Annette von Drygalski, Scott W. J. McPhee, R. Jude Samulski, Ivan Bilic, Maurus de la Rosa, Birgit M. Reipert, Hanspeter Rottensteiner, Friedrich Scheiflinger, John C. Chapin, Bruce Ewenstein, Paul E. Monahan

Blood (2021) 137 (6): 763–774.

https://doi.org/10.1182/blood.2019004625

Published: 2021

Includes: Supplemental data

Journal Articles

AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies

Anita Kruzik, PhD, Roland Raim, PhD, Dirk Voelkel, PhD, Markus Weiller, PhD, Werner Hoellriegl, PhD, Friedrich Scheiflinger, Hanspeter Rottensteiner, Birgit M Reipert, PhD, Maurus de la Rosa

Blood (2019) 134 (Supplement_1): 5922.

https://doi.org/10.1182/blood-2019-126730

Published: 2019

Journal Articles

The Factor VIII Variant X5 Enhances Hemophilia a Gene Therapy Efficiency By Its Improved Secretion

Franziska Horling, PhD, Johannes Lengler, PhD, Wenjing Cao, PhD, Biao Dong, PhD, Bagirath Gangadharan, Maurus De La Rosa, PhD, Werner Hoellriegl, PhD, Birgit M Reipert, PhD, Friedrich Scheiflinger, Weidong Xiao, PhD, Hanspeter Rottensteiner

Blood (2019) 134 (Supplement_1): 3356.

https://doi.org/10.1182/blood-2019-126489

Published: 2019

Journal Articles

Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

Blood (2018) 132 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2018-99-115979

Published: 2018

Journal Articles

The Irish Personalized Approach to the Treatment of Haemophilia (iPATH) - Determinants of Inter-Individual Variation in FVIII Pharmacokinetics

Michelle Lavin, MB, PhD FRCPath, Niamh Larkin, Anjali Patel, Evelyn Singleton, Mary Byrne, Kevin Ryan, MB, FRCPath, Niamh M O'Connell, MB, PhD FRCPath, Birgit M Reipert, Steven Pipe, Peter L Turecek, PhD, James S O'Donnell, MD PhD

Blood (2018) 132 (Supplement 1): 1190.

https://doi.org/10.1182/blood-2018-99-112850

Published: 2018

Journal Articles

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Birgit M Reipert, PhD, Bagirath Gangadharan, PhD, Christoph J Hofbauer, PhD, Fritz Scheiflinger, PhD, Joel Bowen, Elizabeth Donnachie, PhD, Karen Fijvandraat, MD, Ralph A. Gruppo, MD, Jenny Klintman, MD PhD, Christoph Male, MD, Catherine E. McGuinn, MD, Shannon L. Meeks, MD, Michael Recht, MD PhD, M V Ragni, MD, Hassan M Yaish, Elena Santagostino, MD PhD, Deborah L Brown, MD

Blood (2016) 128 (22): 328.

https://doi.org/10.1182/blood.V128.22.328.328

Published: 2016

Journal Articles

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Frank Michael Horling, PhD, Peter Allacher, PhD, Herwig Koppensteiner, PhD, Werner Engl, PhD Cstat, Fritz Scheiflinger, PhD, Brigitt E. Abbuehl, MD, Birgit M Reipert, PhD

Blood (2016) 128 (22): 2594.

https://doi.org/10.1182/blood.V128.22.2594.2594

Published: 2016

Journal Articles

FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors

Christoph J. Hofbauer, Sylvia Kepa, Michael Schemper, Peter Quehenberger, Sylvia Reitter-Pfoertner, Christine Mannhalter, Birgit M. Reipert, Ingrid Pabinger

Blood (2016) 128 (2): 293–296.

https://doi.org/10.1182/blood-2015-10-675512

Published: 2016

Includes: Supplemental data

Journal Articles

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A

Jesse D. Lai, Paul C. Moorehead, Kate Sponagle, Katharina N. Steinitz, Birgit M. Reipert, Christine Hough, David Lillicrap

Blood (2016) 127 (26): 3439–3449.

https://doi.org/10.1182/blood-2015-11-679282

Published: 2016

Includes: Supplemental data

Journal Articles

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Andreas Tiede, Christoph J. Hofbauer, Sonja Werwitzke, Paul Knöbl, Saskia Gottstein, Rüdiger E. Scharf, Jürgen Heinz, Jürgen Groß, Katharina Holstein, Christiane Dobbelstein, Fritz Scheiflinger, Armin Koch, Birgit M. Reipert

Blood (2016) 127 (19): 2289–2297.

https://doi.org/10.1182/blood-2015-09-672774

Published: 2016

Includes: Supplemental data

Journal Articles

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Christoph J. Hofbauer, Shawn F. J. Whelan, Maria Hirschler, Peter Allacher, Frank M. Horling, John-Philip Lawo, Johannes Oldenburg, Andreas Tiede, Christoph Male, Jerzy Windyga, Andreas Greinacher, Paul N. Knöbl, Gerald Schrenk, Jadranka Koehn, Friedrich Scheiflinger, Birgit M. Reipert

Blood (2015) 125 (7): 1180–1188.

https://doi.org/10.1182/blood-2014-09-598268

Published: 2015

Includes: Supplemental data

Journal Articles

Administration of Dexamethasone during Initial Exposure to Factor VIII Prevents the Development of Anti-Factor VIII Antibodies and Increases the Proportion of Thymic but Not Splenic Regulatory T Cells in the Exon 16 Knockout C57Bl6 Hemophilia Α Mouse Model

Maria T. Georgescu, BScH, Paul C. Moorehead, MDMS, MSc, Kate Sponagle, Birgit M. Reipert, PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2014) 124 (21): 237.

https://doi.org/10.1182/blood.V124.21.237.237

Published: 2014

Journal Articles

Immunization Against Influenza but Not MMR Modulates the Anti-Factor VIII Immune Response in Hemophilia Α Mice

Jesse Lai, BSc, Paul C. Moorehead, MDMS, MSc, Kate Sponagle, Katharina Nora Steinitz, PhD, Birgit M Reipert, PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2014) 124 (21): 1501.

https://doi.org/10.1182/blood.V124.21.1501.1501

Published: 2014

Journal Articles

Administration of Dexamethasone during Initial Exposure to Factor VIII Induces Durable and Antigen-Specific Tolerance to Factor VIII in Hemophilia Α Mice with a Humanized Major Histocompatibility Complex II Transgene

Paul C. Moorehead, MDMS, MSc, Maria T. Georgescu, BScH, Alice S. van Velzen, MD, Kate Sponagle, Barbara Vidal, MSc, Birgit M. Reipert, PhD, Katharina Nora Steinitz, PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2014) 124 (21): 1489.

https://doi.org/10.1182/blood.V124.21.1489.1489

Published: 2014

Journal Articles

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

Shawn F. J. Whelan, Christoph J. Hofbauer, Frank M. Horling, Peter Allacher, Martin J. Wolfsegger, Johannes Oldenburg, Christoph Male, Jerzy Windyga, Andreas Tiede, Hans Peter Schwarz, Friedrich Scheiflinger, Birgit M. Reipert

Blood (2013) 121 (6): 1039–1048.

https://doi.org/10.1182/blood-2012-07-444877

Published: 2013

Includes: Supplemental data

Journal Articles

Surgical Injury Alone Does Not Provoke the Development of Factor VIII Inhibitors in Mouse Models of Hemophilia A

Paul C Moorehead, MD, MS, Braden Waters, PhD, Kate Sponagle, Katharina Nora Steinitz, PhD, Birgit M Reipert, PhD, David Lillicrap, MD

Blood (2012) 120 (21): 627.

https://doi.org/10.1182/blood.V120.21.627.627

Published: 2012

Journal Articles

CD4 + T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice

Katharina N. Steinitz, Pauline M. van Helden, Brigitte Binder, David C. Wraith, Sabine Unterthurner, Corinna Hermann, Maria Schuster, Rafi U. Ahmad, Markus Weiller, Christian Lubich, Maurus de la Rosa, Hans Peter Schwarz, Birgit M. Reipert

Blood (2012) 119 (17): 4073–4082.

https://doi.org/10.1182/blood-2011-08-374645

Published: 2012

Includes: Supplemental data

Journal Articles

Preclinical Immunogenicity Assessment of Baxter‘s Longer-Acting FVIII Candidate BAX 855 Using Novel Preclinical Models,

Frank M Horling, PhD, Sandra Schwele, PhD, Christian Lubich, Rafi U Ahmad, PhD, Markus Weiller, PhD, Margit Spatzenegger, Hans Peter Schwarz, MD, Birgit M Reipert, PhD

Blood (2011) 118 (21): 3323.

https://doi.org/10.1182/blood.V118.21.3323.3323

Published: 2011

Journal Articles

Preclinical Immunogenicity Assessment of Baxter‘s Recombinant Factor VIIa,

Frank M Horling, PhD, Christine Lenk, Rafi Uddin Ahmad, PhD, Markus Weiller, PhD, Maria Schuster, DVM, Hans Peter Schwarz, MD, Birgit M Reipert, PhD

Blood (2011) 118 (21): 3327.

https://doi.org/10.1182/blood.V118.21.3327.3327

Published: 2011

Journal Articles

Deciphering of CD4 + T Cell Subsets Involved in Maintenance and Break of Immune Tolerance in a Humanized Mouse Model That Is Immune Tolerant to Human FVII

Christine Lenk, Markus Pasztorek, Markus Weiller, PhD, Rafi Uddin Ahmad, PhD, Hans Peter Schwarz, MD, Friedrich Scheiflinger, PhD, Birgit M Reipert, PhD, Maurus de la Rosa, PhD

Blood (2011) 118 (21): 2188.

https://doi.org/10.1182/blood.V118.21.2188.2188

Published: 2011

NARROW

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies

The Factor VIII Variant X5 Enhances Hemophilia a Gene Therapy Efficiency By Its Improved Secretion

Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

The Irish Personalized Approach to the Treatment of Haemophilia (iPATH) - Determinants of Inter-Individual Variation in FVIII Pharmacokinetics

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Administration of Dexamethasone during Initial Exposure to Factor VIII Prevents the Development of Anti-Factor VIII Antibodies and Increases the Proportion of Thymic but Not Splenic Regulatory T Cells in the Exon 16 Knockout C57Bl6 Hemophilia Α Mouse Model

Immunization Against Influenza but Not MMR Modulates the Anti-Factor VIII Immune Response in Hemophilia Α Mice

Administration of Dexamethasone during Initial Exposure to Factor VIII Induces Durable and Antigen-Specific Tolerance to Factor VIII in Hemophilia Α Mice with a Humanized Major Histocompatibility Complex II Transgene

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

Surgical Injury Alone Does Not Provoke the Development of Factor VIII Inhibitors in Mouse Models of Hemophilia A

CD4 + T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice

Preclinical Immunogenicity Assessment of Baxter‘s Longer-Acting FVIII Candidate BAX 855 Using Novel Preclinical Models,

Preclinical Immunogenicity Assessment of Baxter‘s Recombinant Factor VIIa,

Deciphering of CD4 + T Cell Subsets Involved in Maintenance and Break of Immune Tolerance in a Humanized Mouse Model That Is Immune Tolerant to Human FVII

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only